Inhaled Nitric Oxide (iNO) is a highly specialized therapy focused on conditions where blood flow and oxygen supply are critically compromised. Its use is typically reserved for critical, high-acuity scenarios in hospital settings. iNO is commonly used to help improve oxygenation and reduce patient burden across several therapeutic domains.

---

This therapy is primarily used for term and near-term newborns with severe hypoxic respiratory failure, often due to conditions like Persistent Pulmonary Hypertension of the Newborn (PPHN), meconium aspiration syndrome, or neonatal pneumonia. It is also relevant in specialized acute contexts, such as the postoperative period following surgery for congenital heart disease in infants and children.

The medication supports patients by addressing symptoms caused by abnormally high resistance in the blood vessels of the lungs (pulmonary hypertension) and critically low oxygen levels in the blood (hypoxemia). It helps address the symptoms caused by the high pressure and supports the flow of blood. This supportive relief may assist with maintaining stability in a high-stress environment.

“This therapy is relevant in acute settings where symptomatic support is needed to manage severe pressure imbalances and improve oxygenation.”

---

Quick Fact: Relief for Cardiovascular Strain iNO helps reduce the pressure the heart must pump against, alleviating severe cardiovascular strain and contributing to easing the overall symptom load during critical episodes.

Eligibility Map: Who Can and Cannot Use Nitric Oxide — Official Regulatory Information

Category	Official Regulatory Statement
Populations Allowed	Term and near-term neonates (mathbfgeq 34 weeks gestational age) with hypoxic respiratory failure associated with pulmonary hypertension.
Absolute Contraindication	Neonates dependent on right-to-left shunting of blood (due to congenital heart disease).
Not Recommended	Premature neonates (< 34 weeks gestational age) are not recommended for routine use, as clinical benefit has not been established.
Age Restriction	The medicine is not indicated for older infants, children, adults, or the geriatric population.
Conditional Restriction	Use requires caution and close monitoring for Methemoglobinemia and in neonates with pre-existing left ventricular dysfunction.
Pregnancy/Lactation	Not established; the medicine is not indicated for use in the adult population.

Official regulatory documents define the eligibility profile of inhaled nitric oxide as highly selective, restricting its approved use to term and near-term neonates. Non-eligibility is defined by absolute contraindications related to cardiovascular anatomy (dependency on right-to-left shunting) and by strict age limitations. Use in other populations is not within the scope of primary regulatory approval.

Nitric oxide has specific interactions primarily related to its effect on the blood and its pathway of action, which are documented in official regulatory labeling.

Interaction Risk

The most clinically significant interaction involves other medicinal products that are nitric oxide donor compounds or agents known to induce methemoglobinemia. Methemoglobinemia is a serious blood condition where a higher-than-normal amount of methemoglobin (a form of hemoglobin) is produced, which impairs the blood’s ability to carry oxygen.

• Increased Methemoglobinemia Risk: Concomitant use with other nitric oxide donors, such as prilocaine, sodium nitroprusside, and organic nitrates (e.g., nitroglycerin), may significantly increase the risk of developing methemoglobinemia. Certain other medicines, including acetaminophen, may also increase this risk.

• Riociguat: The concurrent use of nitric oxide with Riociguat, a soluble guanylate cyclase (sGC) stimulator that acts on the same biological pathway, is generally not recommended. This combination is considered highly clinically significant, with the risk often outweighing the therapeutic benefit.

• Other Interactions: Using nitric oxide with other specific medicines, such as Lidocaine, may require dose adjustments or other precautions, although this combination may be required in some clinical situations. Health professionals assess the risk and benefit on a case-by-case basis.

Molecular Activation of the Soluble Guanylate Cyclase (sGC) Pathway

The core action of inhaled Nitric Oxide ( NO) begins in the pulmonary vascular smooth muscle cells, where the gas binds to and activates the enzyme soluble Guanylate Cyclase ( sGC). This molecular interaction initiates the cGMP signaling cascade, which results in a significant reduction of intracellular calcium ( Ca^2+) levels essential for causing vascular smooth muscle relaxation.

Selective Pulmonary Vasodilation and Blood Flow Redirection

The smooth muscle relaxation is highly localized, producing vasodilation only in the blood vessels adjacent to the NO-rich, well-ventilated regions of the lung. This targeted lowering of Pulmonary Vascular Resistance ( PVR) redirects blood flow away from poorly ventilated lung areas toward the well-ventilated regions. This mechanism improves the Ventilation/Perfusion ( V/Q) ratio, which is the physiological consequence that increases the efficiency of gas exchange.

Constraint by Rapid Systemic Inactivation

The localized action is maintained because any NO that reaches the systemic circulation is immediately and irreversibly scavenged by oxyhemoglobin ( HbO2) within the red blood cells. This rapid molecular inactivation physically restricts the vasodilatory effects, preventing transmission to other organ systems and minimizing effects on systemic blood pressure. This ensures the mechanism is entirely dependent on continuous inhalation.

Inhaled Nitric Oxide (iNO) therapy is a highly specialized medical procedure strictly administered in supervised hospital settings, such as the Neonatal or Adult Intensive Care Unit. The administration route is exclusively by inhalation, delivered continuously as a gas that is precisely diluted into an oxygen/air mixture via a calibrated Nitric Oxide Delivery System (NODS). This method of administration requires mandatory, continuous monitoring of the concentration of the delivered Nitric Oxide and its byproduct, Nitrogen Dioxide.

For term and near-term neonates (greater than 34 weeks gestation), the initial and maximum concentration is uniformly set at 20 ppm (parts per million). The concentration is administered continuously, maintained for the shortest duration necessary, but not typically exceeding 14 days in neonates. For use in other specific contexts, such as certain pediatric or adult patients following cardiac surgery, dosing may be initiated at 10 ppm to 20 ppm, with established clinical parameters for increases up to 40 ppm.

The therapy is delivered as a continuous flow, and thus is not administered in scheduled doses that can be missed. Discontinuation of the medicine must follow a defined, stepwise weaning protocol. Established clinical protocols strictly forbid abrupt discontinuation of Nitric Oxide therapy, mandating a gradual reduction in concentration (e.g., to 5 ppm, then to 1 ppm) over a specified time period.

Research Evidence / Overview of Studies for Inhaled Nitric Oxide

This overview describes the types of clinical studies that have been conducted for Inhaled Nitric Oxide and what they examined, based on authoritative scientific and regulatory findings. It focuses strictly on the evidence landscape without offering medical advice or treatment instructions.

---

Evidence for Use in Newborns with Severe Respiratory Failure

Research exploring the use of inhaled nitric oxide in term and near-term newborns (those ge 34 weeks gestational age) with severe breathing difficulties often associated with high pressure in the lungs is supported by evidence from Randomized Controlled Trials (RCTs) and subsequent systematic reviews. These short-term studies were used in research examining patterns in patient oxygen status and the rate of use of certain medical procedures.

In these trials, studies monitored physiological strain or stress and recorded patient outcomes related to systemic or functional imbalance. Findings describe patterns observed in the studies, where researchers tracked the rate of use of Extracorporeal Membrane Oxygenation (ECMO), which is a specialized machine that temporarily acts as the heart and lungs. Research also highlighted changes measured during the study period related to how well oxygen entered the blood, along with the length of time patients required breathing support (mechanical ventilation).

What remains uncertain is the applicability of these results to all patients. While the core studies focus on older newborns, evidence remains limited for populations including very preterm infants (those born before 34 weeks gestation). Patient outcomes over the long term are not fully established, though some studies monitored developmental patterns in children for up to two years post-treatment. Research is ongoing to better understand these longer-term outcomes.

---

Evidence for Use Following Complex Pediatric Heart Surgery

Inhaled nitric oxide was evaluated in children and infants immediately following certain operations for congenital heart disease. Because this is a specialized acute care context, the research structure includes both Randomized Controlled Trials and large Observational Studies. Research examined temporary physiological imbalance, specifically focusing on outcomes monitoring physiological strain or stress within the first few days after surgery.

Studies monitored changes in measurements of the pressure within the blood vessels of the lungs (pulmonary artery pressure and vascular resistance). Researchers monitored these outcomes related to systemic or functional imbalance as part of the evidence collection. The findings reported how symptoms evolved in the observed populations, and the evidence derived from settings with varying symptom burdens monitored the time required before a patient could be successfully removed from mechanical ventilation.

---

What is Still Uncertain About the Research for Inhaled Nitric Oxide

While The research base for inhaled nitric oxide exists for its approved uses in newborns, findings describe group patterns, not personal outcomes, and several areas remain under investigation.

The evidence quality varies across studies for less common or complex uses, particularly in adults or certain complex cardiac conditions. Furthermore, research highlights what is known and what is still uncertain regarding patient outcomes over the long term beyond initial childhood follow-up. The main limitation remains the lack of comprehensive long-term data tracking patient health and functional status over many years.

Common questions about Nitric Oxide (FAQ)

---

Q: How is the prescription drug Nitric Oxide different from Nitric Oxide supplements for exercise?

The prescription medicine, Nitric Oxide, is a pure gas administered by inhalation in a hospital setting for an immediate, selective effect on the blood vessels in the lungs. This is distinct from dietary supplements, which are often taken orally to support the body's natural Nitric Oxide production for a more general, systemic effect on blood flow. Regulatory oversight differs, as the medical gas is a prescription drug, while the supplements are classified differently.

Q: What is the main difference between Nitric Oxide (the medicine) and Nitrous Oxide (laughing gas)?

According to official product information, the primary difference is their chemical composition and function. Nitric Oxide ( NO) medicine is a reactive gas used specifically to widen blood vessels in the lungs, a process called selective vasodilation. In contrast, Nitrous Oxide ( N2 O or laughing gas) is an inert gas used primarily for its anesthetic and analgesic properties.

Q: What is methemoglobinemia, and is it a possible side effect of Nitric Oxide?

Methemoglobinemia is a serious, documented side effect of Nitric Oxide treatment. It occurs when a form of hemoglobin is produced that cannot effectively carry oxygen to the body’s tissues. Official product information notes this is a dose-dependent reaction, and monitoring of methemoglobin levels is required during treatment.

Q: How quickly does the medical effect of Nitric Oxide typically begin?

Official product information indicates that the therapeutic effect of inhaled Nitric Oxide is immediate. This rapid action occurs because the gas is delivered directly into the lungs where it quickly relaxes the blood vessels.

Q: Is it safe to be given Nitric Oxide if a patient is taking other heart or blood pressure medications?

Regulatory documents advise that using Nitric Oxide alongside certain other medicines, such as vasodilators or blood pressure medications, may increase the potential for adverse effects. Combining it with medicines that increase methemoglobin levels also carries a specific risk. A healthcare provider assesses the risk and benefit of combining these medicines based on the patient’s condition and regulatory guidance.

Q: Does Nitric Oxide interact with prescription medications for erectile dysfunction?

Yes, official regulatory information confirms that Nitric Oxide is known to interact with certain prescription medications used for erectile dysfunction, known as PDE5 inhibitors. Official guidance states this combination may cause a significant drop in blood pressure, necessitating close clinical monitoring.

Q: What are the common signs of an unwanted reaction to Nitric Oxide that a caregiver should watch for?

Caregivers are advised to watch for signs that can indicate a serious adverse effect, such as methemoglobinemia or a sudden drop in blood pressure. These signs include the lips or skin appearing bluish, confusion, or feelings of lightheadedness and dizziness. It is important that any such changes are promptly reported to the healthcare team.

Q: What is the role of Nitric Oxide in the human body naturally, before it is given as a medicine?

Before it is used as a medicine, Nitric Oxide is a naturally occurring signaling molecule produced by cells throughout the body. Regulatory-supported research indicates it plays a vital role in regulating the relaxation and widening of blood vessels (vascular tone), local blood flow, and various host defense mechanisms.

Q: What does the term 'hypoxic respiratory failure' that Nitric Oxide treats mean?

Hypoxic respiratory failure is the severe breathing condition where the amount of oxygen reaching the blood drops to dangerously low levels. Inhaled Nitric Oxide is used to treat this condition when it is specifically associated with high pressure in the blood vessels of the lungs (pulmonary hypertension).

Q: Is it normal for a patient to experience dizziness or lightheadedness while receiving Nitric Oxide?

Dizziness, faintness, and lightheadedness are documented adverse effects of Nitric Oxide treatment. These symptoms are often related to a decrease in the patient's overall blood pressure, which is a known effect of the medicine.

Q: Why is Nitric Oxide sometimes mentioned in articles about athletic or sexual performance?

This confusion often arises because the prescription drug shares a name with dietary supplements. These supplements are promoted to boost the body’s natural nitric oxide production for general systemic vasodilation related to performance. However, the prescription medicine is the pure gas used only in a hospital setting for selective pulmonary effects.

Q: Why is Nitric Oxide sometimes studied in relation to adult lung conditions like ARDS?

While inhaled Nitric Oxide is not approved for use in adult Acute Respiratory Distress Syndrome ( ARDS), research evidence indicates it has been studied as a potential supportive measure to temporarily improve low blood oxygen levels in certain critically ill adult patients.

Q: Are there known risks related to the equipment used to deliver inhaled Nitric Oxide gas?

The specialized delivery system required for this medicine must continuously monitor the gas concentration and levels of the byproduct, nitrogen dioxide ( NO2). Continuous monitoring of the system is required to help mitigate equipment-related risks, such as a malfunction that could lead to improper gas delivery or toxic exposure.

Q: What are the possible effects of Nitric Oxide on liver or kidney function?

Official documents indicate that an increased risk of renal toxicity (kidney impairment) has been observed in some critically ill patients receiving the medicine. This risk is particularly associated with higher concentrations or prolonged use. For this reason, kidney function is typically monitored during the course of treatment.

Q: Why might a patient who is dependent on a right-to-left shunt not be a candidate for this treatment?

Official regulatory documents note this condition as a contraindication. The medicine can potentially reverse the shunting of blood, which is the flow pathway these patients rely on for systemic circulation. Reversing this flow can lead to a significant and dangerous decrease in blood flow to the rest of the body.

Q: Does Nitric Oxide interact with any common herbal products or dietary supplements?

Official regulatory warnings advise that patients or caregivers should discuss the use of any non-prescription OTC medicines, herbal products, or dietary supplements with a health professional. This precaution is stated because potential interactions may occur that could affect safety or effectiveness.

Q: What is the required standard for training and supervision for administering Nitric Oxide?

Regulatory guidelines indicate that the medicine is to be administered under the supervision of a clinician or trained health professional. This professional must be experienced in the proper use, administration, and potential hazards associated with medical gas mixtures.

Q: Does receiving Nitric Oxide affect the results of routine blood tests?

Yes, the medicine can affect blood test results related to blood oxygen carrying capacity and clotting factors. Official information indicates a potential dose-dependent increase in methemoglobin levels and a possible decrease in platelet count (thrombocytopenia), both of which typically require monitoring by the care team.

Q: What are the symptoms of an overdose of inhaled Nitric Oxide?

Symptoms of an overdose are typically linked to dangerously high levels of methemoglobin in the blood. These may include the patient's lips or skin appearing blue, a rapid heart rate, headache, dark urine, or unusual bleeding.

Q: How is the patient’s condition monitored while they are receiving Nitric Oxide?

Patient monitoring is continuous and rigorous while receiving this medicine. This process includes checking the concentration of the delivered gas and its byproduct, nitrogen dioxide. Additionally, healthcare staff perform periodic checks of the patient's blood (such as methemoglobin levels) and vital signs, including heart rate and blood pressure.

Nitric oxide is supplied as a compressed gas in cylinders, which require specific storage and handling to maintain product stability and safety. Cylinders must be kept out of reach of children and stored in a secured, upright position to prevent falling. They should be protected from physical damage, freezing, and temperatures exceeding 52 C (125 F), as excessive heat may cause rupture. The container label must not be removed or altered.

Only use the gas when the cylinder pressure gauge indicates a pressure above the minimum use pressure of 200 psig. The gas is considered stable and usable until the expiration date stamped on the cylinder. Used or empty cylinders should be handled only by qualified personnel and returned to the supplier with the valve closed, the valve outlet seal applied, and the protective valve cap in place. Do not dispose of cylinders through regular waste.